Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 11.72
MDVX's Cash-to-Debt is ranked higher than
63% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. MDVX: 11.72 )
Ranked among companies with meaningful Cash-to-Debt only.
MDVX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74  Med: 12.27 Max: No Debt
Current: 11.72
Piotroski F-Score: 2
Altman Z-Score: -14.83
Beneish M-Score: -25.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -607.56
MDVX's ROE % is ranked lower than
99% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. MDVX: -607.56 )
Ranked among companies with meaningful ROE % only.
MDVX' s ROE % Range Over the Past 10 Years
Min: -607.56  Med: -71.81 Max: -26.13
Current: -607.56
-607.56
-26.13
ROA % -435.86
MDVX's ROA % is ranked lower than
98% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.13 vs. MDVX: -435.86 )
Ranked among companies with meaningful ROA % only.
MDVX' s ROA % Range Over the Past 10 Years
Min: -435.86  Med: -66.34 Max: -25.46
Current: -435.86
-435.86
-25.46
ROC (Joel Greenblatt) % -28224.72
MDVX's ROC (Joel Greenblatt) % is ranked lower than
98% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. MDVX: -28224.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDVX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -28224.72  Med: -22094.45 Max: -21078.69
Current: -28224.72
-28224.72
-21078.69
GuruFocus has detected 2 Warning Signs with Medovex Corp $MDVX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDVX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:ZYXI, OTCBB:NAOV, OTCPK:SMLR, OTCPK:CRVW, OTCPK:VASO, NAS:EVAR, OTCPK:ARCRF, OTCPK:GCHIF, OTCPK:SNWV, OTCPK:ABMT, OTCPK:MRIC, NAS:DYNT, AMEX:XTNT, NAS:LLIT, OTCPK:TITXF, NAS:AMDA, NAS:AHPI, OTCPK:NIMU, AMEX:MICR, NAS:AVGR » details
Headquarter Location:USA
Medovex Corp is a development stage company. It is engaged in development, and commercialization of the DenerVex device. Its products include DenerveX Device and the DenerveX Pro-40 power generator.

Medovex Corp was incorporated in Nevada in July 30, 2013. The Company is a development stage company. It is engaged in development, and commercialization of the DenerVex device. It faces competition from medical device, biomedical technology and medical products and combination products companies.

Ratios

vs
industry
vs
history
PB Ratio 7.75
MDVX's PB Ratio is ranked lower than
87% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. MDVX: 7.75 )
Ranked among companies with meaningful PB Ratio only.
MDVX' s PB Ratio Range Over the Past 10 Years
Min: 1  Med: 12.75 Max: 19.12
Current: 7.75
1
19.12
EV-to-EBIT -0.99
MDVX's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 24.65 vs. MDVX: -0.99 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVX' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.4  Med: -1.5 Max: -0.98
Current: -0.99
-3.4
-0.98
EV-to-EBITDA -0.99
MDVX's EV-to-EBITDA is ranked lower than
99.99% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 18.57 vs. MDVX: -0.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDVX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.6  Med: -1.6 Max: -0.98
Current: -0.99
-3.6
-0.98
Current Ratio 5.53
MDVX's Current Ratio is ranked higher than
83% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. MDVX: 5.53 )
Ranked among companies with meaningful Current Ratio only.
MDVX' s Current Ratio Range Over the Past 10 Years
Min: 0.68  Med: 4.83 Max: 19
Current: 5.53
0.68
19
Quick Ratio 5.53
MDVX's Quick Ratio is ranked higher than
88% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MDVX: 5.53 )
Ranked among companies with meaningful Quick Ratio only.
MDVX' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 4.83 Max: 19
Current: 5.53
0.68
19

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.56
MDVX's Price-to-Net-Cash is ranked higher than
59% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 15.75 vs. MDVX: 9.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MDVX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 8.61  Med: 17.53 Max: 110
Current: 9.56
8.61
110
Price-to-Net-Current-Asset-Value 7.82
MDVX's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.69 vs. MDVX: 7.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MDVX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.73  Med: 15.59 Max: 55
Current: 7.82
7.73
55
Price-to-Tangible-Book 7.82
MDVX's Price-to-Tangible-Book is ranked lower than
75% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.84 vs. MDVX: 7.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MDVX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.41  Med: 13.31 Max: 20.52
Current: 7.82
3.41
20.52
Earnings Yield (Greenblatt) % -103.66
MDVX's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. MDVX: -103.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDVX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -105.07  Med: -67 Max: -29.7
Current: -103.66
-105.07
-29.7

More Statistics

EPS (TTM) $ -1.19
Short Percentage of Float1.89%
52-Week Range $0.81 - 1.82
Shares Outstanding (Mil)18.98
» More Articles for MDVX

Headlines

Articles On GuruFocus.com
Medovex Corporation Announces DenerveX System Pre-Production Milestone With Extensive Live Tissue Mo Jun 06 2016 
Medovex Corporation Receives Positive Final Laboratory Test Results Report Jun 02 2016 
Medovex Corporation Attends Spine Week in Singapore May 23 2016 
Medovex Enters Into Service Agreement With LNE/G-MED for Regulatory Services in Preparation for CE M Apr 07 2016 
Medovex Corporation Enters Into International Distribution Agreement With Innosurge Apr 05 2016 
Medovex Corporation Places First Commercial Order for DenerveX(TM) Pro-40 Power Generator in Prepara Mar 07 2016 
Medovex Receives Reimbursement for Its DenerveX Facet Joint Syndrome Treatment in Germany Feb 04 2016 
Medovex Corp. Enters Into Modification Agreement for Previous Loan Financing With Company Co-Founder Jan 26 2016 
Medovex Corporation Announces First DenerveX(TM) System Pre-Production Use in Live Tissue Model Jan 14 2016 
Medovex Corporation to Attend Forum Spine Surgery of the German Spine Society Jan 12 2016 

More From Other Websites
Medovex Corporation Receives First Three Commercial Orders for DenerveX(TM) System Jun 16 2017
Medovex Corporation Releases Letter to Shareholders Jun 12 2017
Medovex Corporation Receives CE Mark Approval for DenerveX(TM) System Jun 05 2017
Medovex Corporation Receives ISO 13485 Certification for the DenerveX(TM) System Jun 01 2017
Medovex Corporation to Attend The NSpine Main Conference June 12-15, 2017 May 08 2017
Medovex Corporation Retains CG Capital as Investor Relations Counsel Apr 13 2017
Medovex Corporation Partners with Technology Consult Berlin GmbH in Germany Apr 05 2017
German Reimbursement Authority Renews Medovex Corporations Reimbursement Payment Coding for the... Mar 13 2017
Medovex Corporation Regains Compliance With Nasdaq Minimum Stockholders' Equity Listing Requirement Mar 02 2017
Medovex Files Form 8K Affirmatively Stating Current Compliance with NASDAQ's Stockholders Equity... Feb 27 2017
Medovex Corporation Provides Corporate Update Feb 21 2017
Medovex Corporation Completes Phase II CE Mark Audit with Notified Body LNE/GMED Feb 15 2017
Medovex Corp. Completes Financing Feb 14 2017
Medovex Corporation Enters into International Distribution Agreement with AlfaMed s.r.l., Italy Jan 11 2017
Medovex Corporation Names Ed Valdez Quality Manager Jan 05 2017
Medovex Corporation Receives SGS Certification for its DenerveX(TM) System Jan 03 2017
Medovex Corp. Completes Sale of Assets of Streamline, Inc. to Skytron, LLC Dec 12 2016
Medovex Corp. Enters Into Modification Agreement for Previous Loan Financing With Company Co-Founder... Jan 26 2016
Medovex Corporation Announces First DenerveX(TM) System Pre-Production Use in Live Tissue Model Jan 14 2016
Medovex Corporation to Attend Forum Spine Surgery of the German Spine Society Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}